GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » Volatility

ACXP (Acurx Pharmaceuticals) Volatility : 59.32% (As of Apr. 06, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2025-04-06), Acurx Pharmaceuticals's Volatility is 59.32%.


Competitive Comparison of Acurx Pharmaceuticals's Volatility

For the Biotechnology subindustry, Acurx Pharmaceuticals's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acurx Pharmaceuticals's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's Volatility distribution charts can be found below:

* The bar in red indicates where Acurx Pharmaceuticals's Volatility falls into.


;
;

Acurx Pharmaceuticals  (NAS:ACXP) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acurx Pharmaceuticals  (NAS:ACXP) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Acurx Pharmaceuticals Volatility Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Acurx Pharmaceuticals Business Description

Traded in Other Exchanges
Address
259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Executives
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David P Luci director, 10 percent owner, officer: President and CEO
Robert J Deluccia director, 10 percent owner 40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Jack H Dean director C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Carl Sailer director 4 GREENBRIAR LANE, MONTVALE NJ 07645
James J. Donohue director C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305
Thomas L Harrison director
Robert G. Shawah officer: Chief Financial Officer C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004